<DOC>
	<DOCNO>NCT01495026</DOCNO>
	<brief_summary>This study open-label , randomize , single dose , multi-stage , cross-over study healthy male subject North East Asian ancestry . The aim : - evaluate pharmacokinetic parameter several formulation fix dose combination ( FDC ) capsule dutasteride tamsulosin hydrochloride ( 0.5 mg/0.2 mg ) relative co-administration dutasteride 0.5 mg capsule tamsulosin hydrochloride 0.2 mg tablet fast state order define formulation bioequivalent 0.2 mg orally disintegrate tamsulosin tablet , ( Harnal-D Tablets ) - determine effect food relative bioavailability tamsulosin FDC product assess bioequivalent Harnal-D Tablets fast state - ass effect water relative bioavailability tamsulosin Harnal-D Tablets fast state - ass safety tolerability dose different FDC capsule formulation Subjects receive single oral dos least one treatment period ; treatment period separate 5-10 day washout period . Blood sample pharmacokinetic analysis take regular interval dose . Safety assess measurement blood pressure , heart rate review adverse event . Each stage study enrol 18 subject ensure 16 complete . Subjects may consent participate one stage .</brief_summary>
	<brief_title>A Study Assessing Range Formulations Fixed Dose Combination Product Containing Dutasteride ( 0.5mg ) Tamsulosin Hydrochloride ( 0.2mg ) Find Formulation Which Bioequivalent Harnal-D Tablets ( Tamsulosin Hydrochloride , 0.2mg ) Healthy Male Subjects From North East Asia</brief_title>
	<detailed_description>This study open-label , randomize , single dose , multi-stage , cross-over study healthy male subject North East Asian ancestry . The aim : - evaluate pharmacokinetic parameter several formulation fix dose combination ( FDC ) capsule dutasteride tamsulosin hydrochloride ( 0.5 mg/0.2 mg ) relative co-administration dutasteride 0.5 mg capsule tamsulosin hydrochloride 0.2 mg tablet fast state order define formulation bioequivalent 0.2 mg orally disintegrate tamsulosin tablet , ( Harnal-D Tablets ) - determine effect food relative bioavailability tamsulosin FDC product assess bioequivalent Harnal-D Tablets fast state - ass effect water relative bioavailability tamsulosin Harnal-D Tablets fast state - ass safety tolerability dose different FDC capsule formulation Subjects receive single oral dos least one treatment period ; treatment period separate 5-10 day washout period . Blood sample pharmacokinetic analysis take regular interval dose . Safety assess measurement blood pressure , heart rate review adverse event . Each stage study enrol 18 subject ensure 16 complete . Subjects may consent participate one stage . BACKGROUND : Dutasteride : Dutasteride ( AVODART â„¢ ) approve potent 5-alpha-reductase inhibitor indicate treatment symptomatic benign prostatic hyperplasia ( BPH ) men enlarge prostate improve symptom , reduce risk acute urinary retention reduce risk need BPH-related surgery [ AVODART Package Insert , 2009 ] . In human , dutasteride well-tolerated single dos 40mg/day , multiple dos 40mg/day administer 7 day , 5 mg/day administer 24 week . In single dose clinical study , overall incidence type adverse event ( AEs ) similar across dutasteride , placebo , finasteride treatment group . Tamsulosin : Tamsulosin ( Harnal , Harnal D , Flomax ) alpha-1-adrenoceptor block agent approve treatment sign symptoms benign prostatic hyperplasia . Tamsulosin HCl extensively metabolize , less 10 % dose excrete urine unchanged [ Harnal , 2009 ; Harnal , 2011 ; Flomax , 2011 ] . In human liver microsome human lymphoblastoid cell express CYP cDNAs vitro , tamsulosin HCl metabolize CYP3A4 CYP2D6 [ Matsushima , 1998 ] . Dutasteride Tamsulosin : Clinical data exist support tamsulosin ( alpha-1-adrenoceptor antagonist ) , use combination dutasteride ( 5-alpha reductase inhibitor ) , offer effective treatment symptom benign prostatic hyperplasia either drug use alone [ GSK study ARI40005 , GlaxoSmithKline document number HM2002/00171/01 ] . In addition , data large , multi-centre National Institutes Health-sponsored Medical Therapy Prostatic Symptoms ( MTOPS ) study reveal great benefit combination alpha-1-adreoceptor antagonist 5-alpha-reductase inhibitor therapy compare either monotherapy male BPH [ McConnell , 2002 ] . Clinical drug interaction study show pharmacokinetic pharmacodynamic interaction dutasteride tamsulosin . Dutasteride may administer without food . Tamsulosin administer food . Food effect PK data exist co-administration dutasteride tamsulosin give fix dose combination ( FDC ) capsule formulation relative co-administration two component , dutasteride tamsulosin HCl ; GSK study ARI109882 , [ GlaxoSmithKline document number ZM2007/00022/00 ] , ARI114694 , [ GlaxoSmithKline document number ZM2010/00028/00 ] . In latter study , dose tamsulosin HCl administer 0.2 mg versus 0.4mg administer ARI109882 . The dose dutasteride study ( 0.5mg ) . In ARI109882 , GSK combination capsule find bioequivalent ( feed fast condition ) market product administer separately . ARI114694 demonstrate bioequivalence dutasteride tamsulosin administer FDC product ( dutasteride 0.5 mg tamsulosin 0.2 mg ) relative co-administration separate commercial formulation dutasteride ( 0.5 mg ) tamsulosin ( 0.2 mg ) fed fast stage different North East Asian ethnic group . A subsequent GSK study , ARI115707 , therefore investigated relative bioavailability tamsulosin ( 0.2mg tamsulosin HCl ) FDC product . Two different enteric-coated formulation tamsulosin administer 3-oblong dutasteride soft gel ( 0.5 mg ) FDC capsule relative co-administration Harnal Capsules Harnal-D Tablets unbranded AVODART ( 0.5mg dutasteride ) . The two FDC formulation consist : 10 % ( weight gain ) enteric coat tamsulosin pellet 3-oblong dutasteride soft gel 15 % ( weight gain ) enteric coat tamsulosin pellet 3-oblong dutasteride soft gel . Specifically , study aim investigate relative bioavailability follow : - FDC ( 10 % enteric coat tamsulosin pellet ) commercial formulation dutasteride plus tamsulosin ( Harnal-D Tablet ) - FDC ( 10 % enteric coat tamsulosin pellet ) commercial formulation dutasteride plus tamsulosin ( Harnal Capsule ) - FDC ( 15 % enteric coat tamsulosin pellet ) commercial formulation dutasteride plus tamsulosin ( Harnal-D Tablet ) ( also investigate ARI114694 ) - FDC ( 15 % enteric coat tamsulosin pellet ) commercial formulation dutasteride plus tamsulosin ( Harnal Capsule ) . ARI115707 result show GSK combination capsule 10 % enteric coat tamsulosin pellet bioequivalent Harnal Capsule . None two GSK formulation find bioequivalent Harnal-D Tablet . In study ARI115708 , relative bioavailability tamsulosin ( 0.2mg tamsulosin HCl ) investigate several different formulation administer 3-oblong dutasteride soft gel FDC capsule relative co-administration Harnal-D Tablets ( 0.2 mg ) unbranded AVODART ( dutasteride , 0.5mg ) . All formulation administer fasted state except last stage effect food FDC assess well effect water administration Harnal-D Tablets . As Harnal Capsules available Korea Japan , bioequivalence Harnal-D Tablets would allow FDC registered China , Korea , Taiwan Japan , Harnal-D Tablets approve . Therefore , ARI115708 , Harnal-D Tablets use comparator .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<criteria>A subject eligible inclusion study follow criterion apply : Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter outside reference range population study may include Investigator GSK Medical Monitor agree find unlikely introduce additional risk factor interfere study procedure . Males 20 45 year age inclusive , time signing informed consent form . Japanese ancestry define born Japan , four ethnic Japanese grandparent , hold Japanese passport identity paper able speak Japanese , Korean ancestry define born Korea , four ethnic Korean grandparent , hold Korean passport identity paper able speak Korean , Chinese ancestry define born China , Hong Kong , Singapore Taiwan , four ethnic Chinese grandparent , hold Chinese passport identity paper able speak Chinese . Japanese , Korean Chinese subject also live outside respective country less 10 year . Male subject female partner childbearing potential must agree use one protocolapproved contraception method . This criterion must follow time first dose study medication 45 day last dose . BMI within range 18 28 kg/m2 ( inclusive ) . Capable give write informed consent , include compliance requirement restriction list consent form . Single QTc &lt; 450 msec ; QTc &lt; 480 msec subject Bundle Branch Block . AST , ALT , alkaline phosphatase bilirubin less equal 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . A subject eligible inclusion study follow criterion apply : Medical Condition Exclusions : Poor metabolizer CYP2D6 substrate determine genotyping select CYP2D6 variant screen . History postural hypotension , dizziness , poor hydration , vertigo , vasovagal reaction sign symptom orthostasis , opinion investigator could exacerbate tamsulosin result put subject risk injury . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . A positive test HIV antibody . Medical Exclusions : Subjects must able willing refrain use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort , Black Khosh , Dong Quai , Milk Thistle , licorice ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . History sensitivity tamsulosin HCl dutasteride , component thereof drug class history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . A history sensitivity heparin heparininduced thrombocytopenia The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Lifestyle Exclusions : A positive prestudy drug/alcohol screen . A minimum list drug screen include amphetamine , barbiturate , cocaine , opiates , cannabinoids benzodiazepine . History regular alcohol consumption within 6 month screen visit define follow Australian guideline : Males : An average weekly intake great 21 unit average daily intake great 3 unit . One unit equivalent 270 mL full strength beer , 470 mL light beer , 30 mL spirit 100 mL wine . Subjects must able willing abstain beverage foods contain alcohol 24 hour prior dose day . Consumption red wine , grapefruit juice , grapefruit related hybrid 7 day prior first dose study medication . Where participation study would result donation blood blood product excess 500 mL within 56 day period .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Healthy male subject</keyword>
	<keyword>North-East Asian ancestry</keyword>
	<keyword>Bioequivalence</keyword>
	<keyword>Food effect</keyword>
	<keyword>Tamsulosin hydrochloride</keyword>
	<keyword>Cross-over design</keyword>
	<keyword>Pilot bioequivalence</keyword>
	<keyword>Dutasteride ( GI198745 )</keyword>
</DOC>